Inside our new clinical trial.
350 people. 40 states. 1 probiotic.
Seed promotes DS-01, a probiotic validated in a large clinical trial for bloating and gas, offering 25% off the first month. The trial showed significant improvements in nearly 350 healthy men and women, with nearly 80% reporting minimal discomfort from constipation. Seed highlights the product's proven benefits, including less bloating, gas, and irregularity.
Read this email as text
for screen readers, or when images don't load
25% Off Your First Month of DS-01® ◊
Real Relief, Rigorously Proven
DS-01® is validated in the largest probiotic clinical trial for bloating and gas.¹° That’s a whole new level of proof. | Start DS-01®
Did You Know? | Most probiotic studies are small or only include people with GI conditions. We studied nearly 350 healthy men + women across 40 states and still saw significant improvements. | Start DS-01®
IN OUR CLINICAL TRIAL, NEARLY 80% reported minimal discomfort from constipation.° | 72% reported never or rarely feeling bloated.°
Feel the DS-01® Difference | Less bloating. Less gas. Less irregularity. Time to try the proven probiotic standard.° | Start DS-01®
Citations | ¹In healthy adults, as of February 2026. | °These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. | ◊Offer expires on 8/30/2026 at 11:59 p.m. PT. Offer valid on new DS-01® one-month welcome kits, for a maximum value of $12.50. Offer cannot be combined with any other discounts or promotions.
Pioneering microbial science for human and planetary health since 2015.
This email was sent by Seed.
New York, NY 10013
Seed Health, Inc. 2026
Email headers
sender, ESP fingerprints, unsubscribe and auth headers
As received, minus the delivery side: the archive's own addresses appear as [recipient], relay hops and signatures are left out, and unsubscribe links are trimmed to their host.
- Received-SPF
- pass ([receiver]: domain of [recipient]@mail.seed.com designates 159.112.240.153 as permitted sender) receiver=[receiver]; client-ip=159.112.240.153; envelope-from="[recipient]@mail.seed.com"; helo=outbound153-2.iterable.com;
- Authentication-Results
- [receiver]; dkim=pass header.d=mail.seed.com header.s=mailo header.b=NVbXasGs; dmarc=pass header.from=mail.seed.com policy.dmarc=none; spf=none ([receiver]: no SPF records found for [email protected]) smtp.helo=outbound153-2.iterable.com; spf=pass ([receiver]: domain of [recipient]@mail.seed.com designates 159.112.240.153 as permitted sender) smtp.mailfrom=[recipient]@mail.seed.com; arc=none smtp.remote-ip=159.112.240.153
- X-Mailgun-Sid
- WyI1ZTJkYSIsInNlZWRAaW5ib3hhcmNoaXZlLm9yZyIsIjgwMTUzMyJd
- X-Mailgun-Sending-Ip-Pool-Name
- Primary Iterable Shared
- X-Mailgun-Sending-Ip-Pool
- 5f5906e148d17eb79438cb88
- X-Mailgun-Sending-Ip
- 159.112.240.153
- Sender
- [email protected]
- Date
- Thu, 06 Aug 2026 00:31:54 +0000
- Mime-Version
- 1.0
- Content-Type
- multipart/alternative; boundary="06003bc3ed311e0febe21f00cc4aa535cb834e9e564fc951a85716125bc0"
- Subject
- Inside our new clinical trial.
- From
- Seed <[email protected]>
- X-Message-Id
- 95f0ed5f7c154fa4b740cdd9b7f52f60
- X-Feedback-Id
- 25044624:19182210:79091:iterable
- Reply-To
- [email protected]
- List-Unsubscribe
- <https://links.iterable.com/…>,<mailto:…@unsubscribe.iterable.com>
- X-Campaign-Id
- 19182210
- List-Unsubscribe-Post
- List-Unsubscribe=One-Click
- Feedback-Id
- 25044624:19182210:79091:iterable
- Return-Path
- [email protected]
- X-Mailgun-Variables
- {"metadata": "{\"messageId\":\"95f0ed5f7c154fa4b740cdd9b7f52f60\",\"templateId\":25044624,\"projectId\":18601,\"campaignId\":19182210,\"recipientUserKey\":\"[recipient]\"}"}
- Message-Id
- <[email protected]>
Archived for reference and commentary. Seed, its logos and content are the property of their respective owners; Inbox Archive claims no affiliation and has disabled all links. If you own this content and would like it removed, get in touch.
Similar campaigns from other brands
Different brands running the same play. Compare any of them side by side.
